{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T10:31:56Z","timestamp":1789813916227,"version":"4.0.1"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bone"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.bone.2013.09.023","type":"journal-article","created":{"date-parts":[[2013,10,10]],"date-time":"2013-10-10T01:02:01Z","timestamp":1381366921000},"page":"126-135","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":175,"special_numbering":"C","title":["Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: A systematic review"],"prefix":"10.1016","volume":"58","author":[{"given":"Erik F.","family":"Eriksen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adolfo","family":"D\u00edez-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Boonen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2013.09.023_bb0005","series-title":"Clinician's guide to prevention and treatment of osteoporosis","author":"National Osteoporosis Foundation","year":"2010"},{"key":"10.1016\/j.bone.2013.09.023_bb0010","series-title":"Osteoporosis overview","author":"National Institutes of Health Osteoporosis and Related Bone Diseases National Resource Centre","year":"2012"},{"key":"10.1016\/j.bone.2013.09.023_bb0015","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1046\/j.1532-5415.2003.51110.x","article-title":"Estimating hip fracture morbidity, mortality and costs","volume":"51","author":"Braithwaite","year":"2003","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.bone.2013.09.023_bb0020","series-title":"National hip fracture database national report 2012","author":"The National Hip Fracture Database","year":"2012"},{"key":"10.1016\/j.bone.2013.09.023_bb0025","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1007\/s00198-011-1840-6","article-title":"Regional and age-related variations in the proportions of hip fractures and major fractures among postmenopausal women: the Global Longitudinal Study of Osteoporosis in Women","volume":"23","author":"Pfeilschifter","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2013.09.023_bb0030","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S8756-3282(02)00946-8","article-title":"Long-term efficacy of risedronate: a 5-year placebo-controlled clinical experience","volume":"32","author":"Sorensen","year":"2003","journal-title":"Bone"},{"key":"10.1016\/j.bone.2013.09.023_bb0035","first-page":"657","article-title":"New approaches to pharmacological treatment of osteoporosis","volume":"81","author":"Akesson","year":"2003","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.bone.2013.09.023_bb0040","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","article-title":"Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group","volume":"85","author":"Black","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2013.09.023_bb0045","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2013.09.023_bb0050","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2013.09.023_bb0055","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa022436","article-title":"The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis","volume":"350","author":"Meunier","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2013.09.023_bb0060","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2013.09.023_bb0065","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1185\/03007995.2012.663750","article-title":"Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF)","volume":"28","author":"Cooper","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.bone.2013.09.023_bb0070","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1056\/NEJMp1202623","article-title":"Continuing bisphosphonate treatment for osteoporosis\u2014for whom and for how long?","volume":"366","author":"Black","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2013.09.023_bb0075","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1056\/NEJMp1202619","article-title":"Bisphosphonates for osteoporosis\u2014where do we go from here?","volume":"366","author":"Whitaker","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2013.09.023_bb0080","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","article-title":"Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy","volume":"19","author":"Russell","year":"2008","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2013.09.023_bb0085","author":"Merck Sharp & Dohme Limited"},{"key":"10.1016\/j.bone.2013.09.023_bb0090","author":"Merck Sharp & Dohme Limited"},{"key":"10.1016\/j.bone.2013.09.023_bb0095","author":"Novartis Pharmaceuticals UK Ltd."},{"key":"10.1016\/j.bone.2013.09.023_bb0100","author":"Roche Products Limited"},{"key":"10.1016\/j.bone.2013.09.023_bb0105","author":"Roche Products Limited"},{"key":"10.1016\/j.bone.2013.09.023_bb0110","author":"Warner Chilcott UK Limited"},{"key":"10.1016\/j.bone.2013.09.023_bb0115","author":"Warner Chilcott UK Limited"},{"key":"10.1016\/j.bone.2013.09.023_bb0120","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2013.09.023_bb0125","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2013.09.023_bb0130","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2013.09.023_bb0135","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2013.09.023_bb0140","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2013.09.023_bb0145","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","author":"Black","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2013.09.023_bb0150","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s00223-004-0286-7","article-title":"Seven years of treatment with risedronate in women with postmenopausal osteoporosis","volume":"75","author":"Mellstrom","year":"2004","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.bone.2013.09.023_bb0155","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1007\/s00198-011-1793-9","article-title":"Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension","volume":"23","author":"Bianchi","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2013.09.023_bb0160","first-page":"488","article-title":"Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study","volume":"35","author":"Eisman","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.bone.2013.09.023_bb0165","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1007\/s00198-011-1773-0","article-title":"Efficacy of monthly oral ibandronate is sustained over 5years: the MOBILE long-term extension study","volume":"23","author":"Miller","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2013.09.023_bb0170","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1136\/ard.2005.044958","article-title":"Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2year results from the MOBILE study","volume":"65","author":"Reginster","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.bone.2013.09.023_bb0175","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years' experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2013.09.023_bb0180","first-page":"3109","article-title":"Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group","volume":"85","author":"Tonino","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.bone.2013.09.023_bb0185","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2013.09.023_bb0190","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00223-010-9420-x","article-title":"Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review","volume":"87","author":"Gallacher","year":"2010","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.bone.2013.09.023_bb0195","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1007\/s11999-011-1909-8","article-title":"The effect of antiresorptives on bone quality","volume":"469","author":"Recker","year":"2011","journal-title":"Clin Orthop Relat Res"},{"key":"10.1016\/j.bone.2013.09.023_bb0200","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/jbmr.11","article-title":"Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial","volume":"25","author":"Schwartz","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"S1","key":"10.1016\/j.bone.2013.09.023_bb0205","article-title":"Who is at highest risk for new vertebral fractures after 3years of annual zoledronic acid and who should remain on treatment?","volume":"26","author":"Cosman","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2013.09.023_bb0210","first-page":"64","article-title":"Statistical validation of surrogate endpoints: is bone density a valid surrogate for fracture?","volume":"4","author":"Li","year":"2004","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"10.1016\/j.bone.2013.09.023_bb0215","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1007\/s00198-007-0367-3","article-title":"Zoledronic acid efficacy and safety over five years in postmenopausal osteoporosis","volume":"18","author":"Devogelaer","year":"2007","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2013.09.023_bb0220","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/jbmr.5650111021","article-title":"Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study","volume":"11","author":"Garnero","year":"1996","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2013.09.023_bb0225","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1359\/jbmr.070112","article-title":"Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial","volume":"22","author":"Jamal","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2013.09.023_bb0230","series-title":"FDA drug safety communication: new contraindication and updated warning on kidney impairment for Reclast (zoledronic acid)","author":"US Food and Drug Administration","year":"2012"},{"key":"10.1016\/j.bone.2013.09.023_bb0235","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/ki.2008.193","article-title":"Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women","volume":"74","author":"Boonen","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.bone.2013.09.023_bb0240","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1056\/NEJMc076132","article-title":"Alendronate and atrial fibrillation","volume":"356","author":"Cummings","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2013.09.023_bb0245","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00198-011-1546-9","article-title":"Alendronate and atrial fibrillation: a meta-analysis of randomized placebo-controlled clinical trials","volume":"23","author":"Barrett-Connor","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2013.09.023_bb0250","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid in reducing clinical fracture and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2013.09.023_bb0255","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.bone.2010.05.019","article-title":"Atypical fractures of the femur and bisphosphonate therapy: a systematic review of case\/case series studies","volume":"47","author":"Giusti","year":"2010","journal-title":"Bone"},{"key":"10.1016\/j.bone.2013.09.023_bb0260","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1010650","article-title":"Bisphosphonate use and atypical fractures of the femoral shaft","volume":"364","author":"Schilcher","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2013.09.023_bb0265","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bone.2012.10.016","article-title":"Atypical femoral fractures are a separate entity, characterized by highly specific radiographic features. A comparison of 59 cases and 218 controls","volume":"52","author":"Schilcher","year":"2013","journal-title":"Bone"},{"key":"10.1016\/j.bone.2013.09.023_bb0270","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1002\/jbmr.1565","article-title":"\u201cAtypical femoral fractures\u201d during bisphosphonate exposure in adult hypophosphatasia","volume":"27","author":"Sutton","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2013.09.023_bb0275","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00198-010-1453-5","article-title":"Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report","volume":"22","author":"Rizzoli","year":"2011","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2013.09.023_bb0280","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1056\/NEJMoa1001086","article-title":"Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur","volume":"362","author":"Black","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2013.09.023_bb0285","first-page":"354","article-title":"Summary of ASBMR Task Force on ONJ","volume":"7","author":"Burr","year":"2007","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"10.1016\/j.bone.2013.09.023_bb0290","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2013.09.023_bb0295","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.amjmed.2012.06.023","article-title":"Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday","volume":"126","author":"McClung","year":"2013","journal-title":"Am J Med"},{"issue":"Suppl. 6","key":"10.1016\/j.bone.2013.09.023_bb0300","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1007\/s001980070004","article-title":"Preanalytical variability of biochemical markers of bone turnover","volume":"11","author":"Hannon","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2013.09.023_bb0305","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1007\/s00198-004-1600-y","article-title":"Impact of degenerative spinal diseases on bone mineral density of the lumbar spine in elderly women","volume":"15","author":"Muraki","year":"2004","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.bone.2013.09.023_bb0310","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/jbmr.1570","article-title":"Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk\u2014a perspective","volume":"27","author":"Boonen","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2013.09.023_bb0315","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.bone.2010.12.024","article-title":"The kidney and bisphosphonates","volume":"49","author":"Miller","year":"2011","journal-title":"Bone"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328213003785?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328213003785?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T17:38:39Z","timestamp":1757612319000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328213003785"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":63,"alternative-id":["S8756328213003785"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2013.09.023","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Bone","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bone.2013.09.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}